The Depo-Provera MDL: Case Count, Timeline, and What to Expect

The Depo-Provera meningioma litigation is one of the most significant pharmaceutical mass tort cases currently moving through the federal court system. With more than 3,000 lawsuits filed and key pretrial milestones approaching, understanding where the case stands — and what comes next — is essential for current and prospective claimants. This tracker provides an overview of the MDL’s current status and upcoming events.

Current Status: MDL Overview

The Depo-Provera meningioma cases have been consolidated into a multidistrict litigation (MDL) for coordinated pretrial proceedings. The consolidation was ordered by the Judicial Panel on Multidistrict Litigation (JPML), which determined that centralizing the cases would promote efficient handling of common discovery and pretrial issues.

Key facts at a glance:

• Case count: More than 3,000 individual lawsuits filed as of early 2026, with new cases being added regularly
• Defendant: Pfizer Inc., manufacturer of Depo-Provera and Depo-SubQ Provera 104
• Allegations: Pfizer knew or should have known that its injectable contraceptive was associated with an increased risk of meningioma brain tumors and failed to adequately warn patients and healthcare providers
• Core evidence: The BMJ study establishing a dose-response relationship between injectable progestins and meningioma risk, combined with the FDA’s December 2025 label update formally acknowledging the risk

Litigation Timeline

Phase 1: Filing and Consolidation (2024-2025)

Following the publication of the BMJ study and growing awareness of the Depo-Provera/meningioma link, lawsuits began filing in federal courts across the country. The JPML consolidated these cases into the MDL to prevent duplicative discovery and inconsistent pretrial rulings.

During this phase, the court appointed leadership counsel for the plaintiffs, established case management procedures, and set the framework for discovery. Pfizer was required to begin producing internal documents related to its knowledge of the meningioma risk, its marketing practices, and its communications with the FDA.

Phase 2: Discovery and Expert Development (2025-2026)

The current phase involves extensive discovery — the formal process of exchanging evidence between the parties. Key activities include:

• Document production — Pfizer is producing internal emails, research reports, regulatory submissions, and marketing materials related to Depo-Provera and the meningioma risk
• Depositions — key Pfizer executives, scientists, and regulatory affairs personnel are being deposed by plaintiffs’ counsel
• Expert witness development — both sides are retaining medical experts, epidemiologists, and regulatory experts to support their positions
• Plaintiff fact sheets — individual claimants are completing standardized forms detailing their Depo-Provera use, meningioma diagnosis, treatment, and damages

Phase 3: Rule 702 Hearings — May 2026

One of the most critical upcoming milestones is the Rule 702 hearing (also known as a Daubert hearing), scheduled for May 2026. Under Federal Rule of Evidence 702, the court must evaluate whether the expert witnesses proposed by each side meet the standards for admissibility — that is, whether their testimony is based on reliable scientific methodology and is relevant to the issues in the case.

What this means: If the plaintiffs’ medical and scientific experts survive the Rule 702 challenge, it signals that the court finds their opinions on causation — that Depo-Provera causes meningioma — to be scientifically reliable. This is a significant hurdle. Successful passage strengthens the litigation considerably and often accelerates settlement discussions.

Conversely, if Pfizer successfully excludes key plaintiff experts, it could weaken the litigation. However, given the strength of the published research and the FDA’s own acknowledgment of the risk, plaintiffs’ experts are well-positioned.

Phase 4: Bellwether Selection (Mid-2026)

Following the Rule 702 hearings, the court will select bellwether cases — a small number of representative cases that will proceed to trial first. The bellwether selection process typically involves:

• Both sides proposing candidate cases from the broader pool
• The court selecting cases that represent a range of injury severity, duration of drug use, and other relevant factors
• Intensive case-specific discovery and preparation for the selected cases

Bellwether trials are not binding on other cases in the MDL, but their outcomes have enormous practical significance. Plaintiff verdicts put pressure on defendants to settle; defense verdicts may slow settlement momentum.

Phase 5: Pilot Trial — December 2026

The court has indicated a pilot trial target of December 2026. This will be the first time a Depo-Provera meningioma case is presented to a jury. The pilot trial will test:

• The strength of the general causation evidence (does Depo-Provera cause meningioma?)
• The specific causation evidence in the selected case (did Depo-Provera cause this plaintiff’s meningioma?)
• The adequacy of Pfizer’s warnings
• The damages suffered by the plaintiff

The outcome of this trial — and any subsequent bellwether trials — will heavily influence whether Pfizer proposes a global settlement and at what valuation.

What This Means for Claimants

If You Have Already Filed

Your case is being managed within the MDL framework. During the pretrial phase, your primary obligations are to:

• Complete your plaintiff fact sheet accurately and promptly
• Provide your attorney with updated medical records as needed
• Attend any depositions or examinations scheduled in your case
• Be patient — the MDL process is thorough and takes time, but it is designed to build the strongest possible case

If You Have Not Yet Filed

Now is a critical time to act. Cases filed before the bellwether trials are best positioned to benefit from the full litigation process. Additionally:

• Statutes of limitations impose deadlines for filing — waiting too long may bar your claim entirely
• Earlier filings allow more time for thorough case development
• Your case may be considered for bellwether selection if it represents a strong factual scenario

For a deeper understanding of how this process works, see our guide on how mass tort lawsuits work.

Frequently Asked Questions

How many Depo-Provera lawsuits have been filed?

More than 3,000 individual cases have been filed as of early 2026, with new cases added regularly. The case count is expected to continue growing as awareness of the Depo-Provera/meningioma link increases.

What happens at a Rule 702 hearing?

The court evaluates whether expert witnesses proposed by each side are qualified and whether their opinions are based on reliable scientific methods. This is a gatekeeping function to ensure that only scientifically sound evidence reaches the jury.

Will my individual case go to trial?

Most cases in an MDL do not go to trial individually. The bellwether process tests representative cases, and the results typically lead to settlement negotiations that resolve the broader group. However, if no settlement is reached, individual cases can be remanded to their home courts for trial.

How long will the overall litigation take?

Based on comparable pharmaceutical mass torts, the full process from filing through resolution typically takes 3-5 years. With the pilot trial set for December 2026, meaningful settlement activity could begin in 2027, though individual claim resolution may extend beyond that.

Can I still file a case?

Yes. New cases continue to be filed and added to the MDL. If you used Depo-Provera and were diagnosed with a meningioma, you should consult with an attorney promptly to ensure your claim is filed within the applicable statute of limitations.

Research Methodology

The case counts, timeline, and procedural details in this tracker are sourced from JPML transfer orders, public court dockets in the Depo-Provera MDL, and published reporting on case filing activity. Litigation phase descriptions are based on standard MDL procedures and court scheduling orders.

Limitations

Case counts change frequently as new lawsuits are filed and consolidated, so figures cited here represent a point-in-time snapshot. Court schedules, including the December 2026 pilot trial target, are subject to revision at the court’s discretion, and actual dates may differ from current projections.

Take the Next Step

The Depo-Provera MDL is progressing through critical milestones that will shape the outcome for thousands of women. If you or a loved one developed a meningioma after using Depo-Provera, the time to engage with the legal process is now — before key deadlines pass and while the litigation is still in its formative stages.

If you’ve been affected, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629